Free Trial
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel
NASDAQ:SLDB

Solid Biosciences Q2 2026 Earnings Results & Report

Solid Biosciences logo
$5.56 +0.09 (+1.65%)
As of 09:30 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Solid Biosciences beat analyst earnings expectations in its Q2 2026 results, released August 6, 2026. The company reported EPS of -$0.38 versus the -$0.4624 consensus estimate.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Solid Biosciences EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.4624
Beat/Miss
Beat by +$0.0824
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Solid Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Solid Biosciences' Q3 2026 earnings is estimated for Monday, November 2, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Solid Biosciences' Q2 2026 Press ReleasePress Release
(8-K)
Solid Biosciences' Q2 2026 Quarterly reportQuarterly report
(10-Q)

Solid Biosciences Q2 2026 Earnings FAQ

Solid Biosciences (NASDAQ:SLDB) reported earnings of -$0.38 per share for Q2 2026, beating the consensus estimate of -$0.4624. The report was announced on Thursday, August 6, 2026.

Solid Biosciences' next earnings date is estimated for Monday, November 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for Solid Biosciences on the company's earnings history page.

Solid Biosciences Earnings Headlines

Solid Biosciences Inc. (NASDAQ:SLDB) Receives Average Recommendation of "Moderate Buy" from Brokerages
October 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31101636
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3373376/0/en/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.tc pixel
October 15 at 1:00 AM  |  Altimetry (Ad)
Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy's Limitations
September 25, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4949710-solid-biosciences-a-funded-challenge-to-duchenne-gene-therapys-limitations
RBC Capital initiates coverage of Solid Biosciences at outperform
September 17, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/rbc-capital-initiates-coverage-of-solid-biosciences-at-outperform/ar-AA2coj9z
Solid Biosciences' Duchenne Muscular Dystrophy Approach, FDA Shift Support Upside, RBC Says
September 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/solid-biosciences-apos-duchenne-muscular-151612527.html
See More Solid Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Solid Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Solid Biosciences and other key companies, straight to your email.

About Solid Biosciences

Solid Biosciences (NASDAQ:SLDB) is a biotechnology company focused on developing genetic medicines for patients with rare diseases. The company’s research platform is centered on adeno-associated virus (AAV) gene therapy and other genetic medicine technologies intended to address the underlying causes of disease.

Solid Biosciences’ lead program is SGT-003, an investigational gene therapy being developed for Duchenne muscular dystrophy, a severe inherited neuromuscular disorder. The company is also developing additional programs for rare cardiac and neuromuscular conditions, including SGT-501 for BAG3-associated dilated cardiomyopathy. These candidates remain in clinical or preclinical development, and the company does not have an approved commercial product.

Founded in 2013, Solid Biosciences is headquartered in the United States and conducts research and clinical development activities through U.S.-based operations and collaborations. The company is led by Chief Executive Officer Bo Cumbo. Its programs are designed for patients with serious rare diseases in the United States and potentially other markets, subject to clinical and regulatory outcomes.

View Solid Biosciences Profile
Earnings Tools